SAN
MATEO, Calif., Sept. 6,
2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
(Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company
focused on the development and commercialization of innovative
therapies for use in medically supervised settings, today announced
that Chief Executive Officer, Vince
Angotti will present in-person and be available for
one-on-one meetings throughout the H.C. Wainwright 25th
Annual Global Investment Conference being held September 11-13, 2023 in New York, NY.
H.C. Wainwright Annual Investment Conference
Format:
Live presentation and 1x1 Meetings
Presentation date: Tuesday, September
12th, 2023
Presentation time: 5:00 PM EDT
Webcast Link: [CLICK HERE]
The recorded presentation will also be available for 90 days
on AcelRx's website within the
Investors/News/Events section.
This release is intended for investors only.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for use in medically supervised settings.
AcelRx's lead product candidate, Niyad™ is a lyophilized
formulation of nafamostat and is currently being studied under an
investigational device exemption, or IDE, as an anticoagulant for
the extracorporeal circuit, and has received Breakthrough Device
Designation Status from the FDA. AcelRx is also developing two
pre-filled syringes in-licensed from its partner Aguettant:
Fedsyra™, a pre-filled ephedrine syringe, with an expected NDA
filing in 2023, and PFS-02, a pre-filled phenylephrine syringe with
an expected NDA filing in 2024.
This release is intended for investors only. For additional
information about AcelRx, please visit www.acelrx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-participate-in-the-hc-wainwright-annual-investment-conference-301918912.html
SOURCE AcelRx Pharmaceuticals, Inc.